CLINICAL_TRIALS
trial_result
· 2021-06-30
Clinical Trial Update: Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） [Phase 2]
Summary
Phase 2 trial update evaluating carelizumab in combination with regorafenib for hepatocellular carcinoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN